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Abstract:  
Objectives: Significant alterations in the pharmacokinetics (PK) of antimicrobials have been reported 
in critically ill patients. We describe PK parameters of imipenem in intensive care unit (ICU) patients 
with suspected ventilator-associated pneumonia (VAP) and evaluate several dosage regimens. 
Methods: This French multicentre, prospective, open-label study was conducted in ICU patients with 
a presumptive diagnosis of Gram-negative bacilli VAP who empirically received imipenem I.V. q8h. 
Plasma imipenem concentrations were measured during the 4th imipenem infusion using 6 samples 
(trough, 0.5, 1, 2, 5 and 8 hours). Data were analysed with a population approach using the SAEM 
algorithm in Monolix 4.2. A Monte Carlo simulation was performed to evaluate six dosage regimens: 
500, 750 or 1000mg with administration q6h or q8h. The pharmacodynamic target was defined as 
the probability of achieving a fractional time (fT) above minimum inhibitory concentration (MIC) 
greater than 40%.  
Results: Fifty-one patients were included in the PK analysis. Imipenem concentration data were best 
described by a two-compartment model with three covariates (creatinine clearance, total body 
weight and serum albumin). Estimated clearance (between-subject variability) was 13.2 L/h (38%), 
and estimated central volume 20.4 L (31%). At an MIC of 4 µg/mL, the probability of achieving 40% fT 
>MIC was 91.8%, for 0.5-h infusions of 750mg q6h, 86.0% of 1000mg q8h and 96.9% of 1000mg q6h.  
Conclusion:  
This population PK model accurately estimated imipenem concentrations in ICU patients. The 
simulation showed that for these patients the best dosage regimen of imipenem is 750mg q6h and 
not 1000mg q8h.  
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What is already known about this subject? 
In critically ill patients, there are significant alterations in antimicrobials pharmacokinetics (PK) and 
high MICs bacteria. Pharmacodynamic target for imipenem, widely used in this specific population, is 
based on time over MIC, but few data is available for imipenem PK in these patients and dosage 
regimen have not been evaluated. 
What this study adds? 
Using a PK population approach, our study showed in critically ill patients a slight increased clearance 
and twice increased distribution volume of imipenem, compared to healthy patients. We also 
demonstrated that for 2-to-4 µg/mL MICs bacteria, a 750 mg q6h dosage regimen allowed to reach a 
40% fractional time over MIC. 
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Introduction  
Imipenem was the first licensed antibiotic of the carbapenem class and has been widely used for 
more than 30 years, for hospital-related infections caused by resistant Gram-negative bacilli. Due to 
its broad spectrum, imipenem is often prescribed for initial empirical treatment of ventilator-
associated pneumonia (VAP) in critically ill patients with risk factors for multidrug-resistant Gram-
negative bacilli (1,2). It is a hydrophilic molecule characterised by a half-life (𝑡1 2⁄ ) of one hour, low 
plasma protein binding (< 20%) and predominantly renal excretion unchanged close to 70% (3,4). In 
healthy subjects, the clearance is 12.1 L/h and the volume of distribution (Vd) of the central 
compartment is 9.6 L after 1000 mg every 8 hours (q8h) with 0.5-hour infusion (5). Imipenem has a 
time-dependent bactericidal activity and the pharmacodynamic (PD) parameter associated with its 
bactericidal effect is the fractional time (fT) when concentration is above the minimum inhibitory 
concentration (MIC). Imipenem has a post-antibiotic effect of 2 to 6 hours against most Gram-
negative bacilli. Antimicrobial activity is optimised when the fraction of time above MIC (fT > MIC) is 
greater than 40% (6,7), but for critically ill patients some studies suggest an optimal fT > MIC of 100% 
(8,9). 
In critically ill patients , the pharmacokinetic (PK) properties of drugs are modified with an increase in 
Vd, fluctuation of plasma clearance, presence of oedema, and drug-drug interaction (10–13), 
resulting in a lesser or higher drug exposure.  
In addition to changes in PK characteristics of ICU patients, there is a worrisome increase in the 
incidence multiresistant Gram-negative bacilli, especially in the ICU. In this context, dosage regimens 
of antibiotics in the ICU must be adapted. Currently clinicians tend to increase the doses of 
antibiotics or change the dosage schedule without customizing antibiotic regimens according to the 
host and the offending pathogen. 
Although imipenem is widely used in critically ill patients, data allowing optimisation of its 
administration are surprisingly scarce. Published PK studies with data in these patients are either of 
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imperfect design (14) or have a small number of subjects (15–19). Among these studies, three have 
specifically analysed imipenem PK variability in ICU patients with VAP. 
Some authors have evaluated several dosage regimens of antimicrobials in critically ill patients. For 
aminoglycoside antibiotics, Conil et al. (20) showed the impact of adapting the regimen on PD targets 
(80 < AUC < 125 mg.L-1.h and peak > 10 mg.L-1) after simulation dosage regimens in ICU patients with 
nosocomial infections. For meropenem, an antibiotic of the same class as imipenem, Crandon et al 
(21) evaluated the concentration-time profile in ICU patients with VAP in order to limit the potential 
inadequacies noted for current dosage regimens.  
The aim of our study was to estimate the PK parameters of imipenem and their variability in ICU 
patients with suspected VAP, using a population approach to determine the influence of clinical and 
biological covariates for imipenem. We performed a Monte Carlo simulation to evaluate several 
dosage regimens based on the PD parameter (fT > MIC) for the range of clinical relevant MICs in ICU. 
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Materials and Methods 
Study design and population 
IMPACT, a multicentre, prospective, open-label trial was conducted in three ICUs of two French 
hospitals (Hôpital V Dupouy, polyvalent ICU, Argenteuil, France; AP-HP, Hôpital Bichat, medical ICU 
and surgical ICU, Paris, France). All patients, receiving empirically imipenem I.V. for presumptive 
diagnosis of Gram-negative bacilli VAP, were screened from 2008 to 2010. Inclusion criteria were: (i) 
male or female over 18 years of age, (ii) use of mechanical ventilation for more than 48 hours, (iii) 
clinical suspicion of VAP (1) (new or persistent radiological infiltrate and one of following criteria: 
purulent tracheal aspiration or temperature ≥ 38°3 or leucocytosis > 10000/mL) (iv) VAP with high 
risk of multiresistant bacteria (1) (at least 6 days of mechanical ventilation or antibiotic treatment 
within 15 days). Non-inclusion criteria were (i) time between diagnosis and first antibiotic therapy ≥ 
24 h (ii) expected death within 48 h (iii) creatinine clearance < 10 mL/min or renal replacement 
therapy.  
At inclusion, all patients were treated with a single infusion of amikacin (20 mg/kg) and imipenem 
q8h (500 to 1000 mg) administered as 0.5-hour infusions. The imipenem dose was defined by the 
protocol previously established according to the creatinine clearance estimated by Cockcroft-Gault 
(ClCG) of each patient at inclusion, as recommended by the European Medicine Agency (ClCG>70 
ml/min/1.73 m2: 1000 mg q8h; ClCG>30 ml/min/1.73 m2 and ≤70 ml/min/1.73 m²: 750 mg q8h; ClCG 
≤30 ml/min/1.73 m²: 500 mg q8h). 
The study was conducted in accordance with good clinical practice and was approved by the ethics 
committee (Comité de Protection des Personnes Ile de France I). All patients or their legal 
representative signed an informed consent form. 
Clinical Trial Registration: http://www.clinicaltrials.gov; unique identifier: NCT00950222. 
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Sampling Procedure and Analytical Methods 
Imipenem concentrations were measured at steady state after the 4th dose i.e. between 24 and 32 
hours after the first infusion of imipenem. Six blood samples per patient were collected immediately 
before and at 0.5, 1, 2, 5 and 8 hours after the 4th infusion for concentration measurement. 
Blood samples were retrieved from 4 mL of heparin and immediately centrifuged at 4000 rpm. 
Plasma was then stabilised within ½ hour after collection, by 4-morpholine propane sulphonic acid 
(MOPS) in ethylene glycol and immediately frozen at -80 °C. Plasma imipenem concentrations were 
determined after processing the samples by ultrafiltration, using high-performance liquid 
chromatography (HPLC) on an Interchrome© YP5C18 25QS reverse phase column (length 25 cm, 
internal diameter 4.6 cm). UV detection was performed at 302 nm (22). Chromatographic peaks were 
integrated and imipenem concentrations calculated using Empower 2 software Water®. The lower 
limit of quantification (LOQ) was 0.5 mg/L.  
Blood sample analysis was centralised in the pharmacology-toxicology laboratory of the Hôpital 
Bichat, AP-HP, Paris, France.  
Population pharmacokinetic model building 
Population PK analysis was performed using MONOLIX 4.1.2 software (www.lixoft.eu). Population PK 
parameters were estimated by maximum likelihood using the stochastic approximation expectation 
maximisation (SAEM) algorithm (23). The SAEM algorithm is an expectation maximisation (EM) 
algorithm extension in the nonlinear mixed-effects models where the parameter estimation was 
computed by the maximum likelihood estimator of the parameters without any approximation of the 
model as linearization. Briefly, SAEM converges to maximum likelihood estimates by repeatedly 
alternating between the E and M steps. Then, the expectation of the complete likelihood is 
computed according to a stochastic approximation (25).  
The full maximum likelihood estimation allows to take into account the data below quantification 
limit (BQL) (24). BQL data are considered as left-censored observations, indeed in that case the data 
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𝑦𝑖𝑗 is not observed but we only know that it is below the LOQ. The extension of the SAEM algorithm 
in MONOLIX to consider BQL realized a simulation of the left-censored data in a right-truncated 
Gaussian distribution with an integration below limit of quantification to obtain probability of BQL. It 
is very similar to the method call ‘M3’ in NONMEM for handling BQL data (26). 
  
Structural and statistical model 
In the first step, a basic population PK model without covariates was developed. For the structural PK 
model, one- and two-compartment models were compared. Exponential random effects were 
assumed to describe between-subject variability: e.g. for clearance (CL) of subject i,  𝐶𝐿𝑖 =  𝐶𝐿𝑝𝑜𝑝 ×
e𝜂𝐶𝐿,𝑖  where 𝐶𝐿𝑝𝑜𝑝 is the population parameter estimate, 𝜂𝐶𝐿,𝑖 is the individual random effect. The 
random effects were first supposed to be independent with diagonal variance-covariance matrix Ω 
and then possible correlations between random effects were tested in this variance-covariance 
matrix. Additive, proportional and combined error models were tested. The most appropriate 
pharmacostatistical model was selected on the basis of the following criteria: (i) smaller value of 
Bayesian information criterion (BIC); (ii) adequate goodness-of-fit (GOF) plots; (iii) low relative 
standard error (RSE) in estimated PK parameters.  
Covariate analysis 
From the basic model, twelve covariates were studied and chosen for their impact on the PK 
parameters specifically in the ICU in accordance with published data. These 12 covariates were: age, 
gender, total body weight at inclusion and total body weight change (between the 4th dose and 
admission); three specific ICU scores, namely SAPS II (27), the SOFA score (28) and the oedema score 
(ES) (29); serum albumin and four-hour creatinine clearance (CrCl4h) (30); positive end-expiratory 
pressure (PEEP), PaO2/FiO2 ratio, and the presence of septic shock. These covariates were recorded 
at the 4th dose of imipenem except for SAPS II and weight, which were measured both at admission 
and inclusion. Urine samples for CrCl4h were collected when the 4th infusion of imipenem had started. 
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CrCl measurement over 4 hours was assumed to be a true reflection of renal function during the 4th 
infusion (31,32). Missing values for tested covariates were imputed to the median value observed in 
the analysis population. 
The parameter-covariate relationships were modelled multiplicatively as follows (e.g. for imipenem 
clearance CL): for continuous covariates, 𝐶𝐿𝑖 =  𝐶𝐿𝑝𝑜𝑝 × (
𝐶𝑂𝑉𝑖
𝐶𝑂𝑉𝑚𝑒𝑑𝑖𝑎𝑛
)𝛽 × e𝜂𝐶𝐿,𝑖 where 𝛽 is the 
covariate effect to be estimated, 𝐶𝑂𝑉𝑖 is the value for the subject 𝑖; 𝐶𝑂𝑉𝑚𝑒𝑑𝑖𝑎𝑛 is the median value 
of covariates; for binary covariates, 𝐶𝐿𝑖 =  𝐶𝐿𝑝𝑜𝑝 × 𝑒
𝛽.𝐶𝑂𝑉𝑖 × e𝜂𝐶𝐿,𝑖  where 𝐶𝑂𝑉𝑖  takes a value of 0 or 
1. For all covariates, binary or continuous, the unit of 𝛽 is the log of the unit of the associated 
parameter. 
Covariates were selected with a forward method using BIC (33). First, a model with one covariate was 
selected with the smallest BIC. Then, the model with two covariates was selected similarly. The 
addition of covariates was stopped when no further decrease of BIC was obtained. The covariates 
model was finalised with a backward selection, removing covariates one by one, using the Likelihood 
Ratio Test (LRT). A covariate was retained in the model if the LRT was significant (p < 0.05) when it 
was removed from the full model. In the final model, the 95% confidence interval of each parameters 
was determined from 1000 nonparametric bootstraps based resampling (34).  
Model evaluation 
Evaluation of the model was based on GOF plots. The model was first evaluated using observations 
versus individual and population predictions plots and usual residual-based plots (individual 
weighted residuals [IWRES] plot and population weighted residuals [PWRES] plot). It was then 
assessed using simulation-based plots, (visual predictive check (VPC) plot and normalised prediction 
distribution error (NPDE) versus time. The VPC plot showed the 10th, 50th, and 90th percentiles of 
observed data over time and their corresponding 90% prediction intervals calculated from 500 
Monte Carlo samples (simulated using the model, the parameter estimates and the design of the 
dataset). NPDE was built from the percentile derived from VPC prediction. The plot of NPDE takes 
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into account the full predictive distribution of each individual observation and the various imipenem 
doses. As only few patients had different doses of imipenem and as we plot NPDE, we did not 
perform a prediction corrected VPC (35). 
Model evaluation was performed for both the basic model and the final model with covariates. 
Monte Carlo simulation for dosage regimen evaluation 
A Monte Carlo simulation was performed using the final PK model with covariates to predict the 
distribution of plasma imipenem concentrations and to estimate the PD parameter fT > MIC for 
several current dosage regimens and various MIC values. Six usual dosage regimens were studied: 
500, 750 and 1000 mg with administration q6h or q8h. We simulated 1000 patients with a set of 
covariates re-sampled among the observed covariates of included patients and a vector of random 
effects drawn from the estimated distribution. The concentration-time profile of the 1000 virtual 
patients was simulated at steady state for the six dosage regimens. 
The MIC targets were selected from the European Committee on Antimicrobial Susceptibility Testing 
(EUCAST(36)) data and ranged from 0.06 to 32 µg/mL. Two specific MIC, 2 µg/mL and 4 µg/mL, were 
studied. These MICs were the limited sensitivity breakpoint of imipenem currently observed for 
Gram-negative bacilli isolated in the ICU (Enterobacteriaceae species and Pseudomonas aeruginosa, 
respectively).  
The time for which the imipenem concentration remained above the MIC at steady state was 
calculated as a cumulative percentage over a 24-hour period and the probability of 
pharmacodynamic target attainment (PTA) was assessed as a fraction that achieved 40% fT > MIC or 
100% fT > MIC. 
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Results 
Patients 
Sixty-three patients were included in the IMPACT study. Twelve patients were excluded from the PK 
analysis: three lacking a kinetic profile and nine who did not receive four doses of imipenem. Fifty-
one patients were included in the PK analysis, 41 of whom were males (80%), ranging in age from 28 
to 84 years (median 60 years). At inclusion, median total body weight was 77 kg (range [45-126]). All 
patient characteristics are summarised in Table 1. Reasons for admission to the ICU were medical in 
40 patients (78%) and surgical for 11 patients (22%), and the SAPS II at admission was 43 [17-80]. The 
median duration of stay in the ICU and of mechanical ventilation before inclusion was 8 days [1-60] 
and 8 days [5-60], respectively. Antibiotic therapy was prescribed to 48 patients (94%) in the three 
months before admission, including 11 patients (30%) who previously received imipenem.  
Four patients (9%) received 500 mg of imipenem, 15 (29%) 750 mg and 32 (62%) 1000 mg with the 
same dose interval q8h.  
Population pharmacokinetic analysis 
A total of 297 samples were available for PK modelling with a median of 6 samples [3-6] per 
individual (Figure 1). Imipenem concentrations at peak (0.5 h) and trough were 34.1 mg/L [12.3-67.5] 
and 1.9 mg/L [0.5-10.1], respectively. Nine percent of imipenem concentrations were below the limit 
of quantification (BQL). One patient received the 4th dose 5 hours late. 
Imipenem PK concentrations were best described by a two-compartment model. An exponential 
random effects model described the between-subject variability in clearance CL and volume of 
distribution of the central compartment V1. Since the variability of intercompartmental clearance Q 
and the volume of distribution of the peripheral compartment V2 were very low, the between-
subject variability was not estimated and was taken as zero. A proportional model was used to 
describe the residual variability.  
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As shown in Table 2, estimated imipenem CL was 13 L/h, Q 10.1 L/h and the volumes V1 and V2 were 
22.4 L and 9.9 L, respectively. A correlation between CL and V1 was retained in the basic model and 
estimated as 0.48. The GOF plots of the basic model were satisfactory (plots not shown). 
Model with covariates 
The best model with one covariate included the effect of 4-hour creatinine clearance (CrCl4h) on CL. 
Covariate selection was continued up to a model with four covariates; the model with five covariates 
had a larger BIC (Table 3).  
The backward selection was then performed from the model with the four following covariates: 
CrCl4h, age, serum albumin and total body weight. Only three covariates were significant using the 
LRT and kept in the final model: CrCl4h on CL, serum albumin (imputed to median value for 8 patients 
with missing data) and total body weight on V1. Imipenem CL was found to increase with CrCl4h. V1 
was found to increase with total body weight and decrease with serum albumin (Figure 2).  
The introduction of CrCl4h alone reduced the variability of CL (ωCL) from 48% to 38%. The introduction 
of weight and serum albumin reduced the variability of V1 from 48% to 31%. The final PK parameters 
are summarised in Table 2.  All were reliably estimated, as reflected by the small RSEs from observed 
Fisher Information Matrix. The results of bootstrap medians and 95% CI were consistent except for 
the between-subject variability ωV1 and the correlation. Nevertheless the bootstrap analysis 
confirmed the reliability and robustness of the parameter estimates and thus the final model with 
covariates was representive. Estimated parameters were similar in the analysis of the 43 patients 
with no missing albumin data (results not shown). 
Model evaluation 
The GOF plots of the final PK model with covariates are shown in Figure 3 and Figure 4. The model 
adequately described the observations as shown by the plots of observations versus population and 
individual predictions with the exception of the highest concentrations. Moreover, the NPDE plot 
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versus predictions and the IWRES show no trend. The VPC plot and the NPDE plot presented in Figure 
4 as a function of time from first dose indicate a good predictive performance of the model. 
Monte Carlo simulation for dosage regimen evaluation 
Using the simulated concentration-time profiles at steady-state, the PTA (40% or 100% fT > MIC) was 
calculated for the current dosage regimens 500, 750 and 1000 mg q6h or q8h. As shown in Figure 5 
(a), all simulated patients had a fT > MIC greater than 40% for MIC from 0.06 to 1 µg/mL for the 6 
dosage regimens. For MIC = 2 µg/mL, 86% of patients had the PTA at 40% with 500 mg q8h, 96.9% 
with 500 mg q6h; 95.3% with 750 mg q8h, 99.1% with 750 mg q6h; 97.9% with 1000 mg q8h and 
99.4% with 1000 mg q6h. Figure 5 (b) shows the probability of fT > MIC greater than 100% with the 6 
different dosage regimens. The percentage of patients was higher with the q6h regimen than with 
the q8h regimen, whatever the dose. For MIC = 4 µg/mL, 5% of simulated patients had the PTA at 
100% with 500 mg q8h and 18.7% with 500 mg q6h; 14.3% with 750 mg q8h and 32.5% with 750 mg 
q6h; 20.9% with 1000 mg q8h and 45% with 1000 mg q6h. 
These results were confirmed by the simulated median concentration-time profile after four doses of 
imipenem (study protocol) as shown in Figure 6. The median patient with the 1000 mg q8h regimen 
did not achieve the PD target of MIC = 2 µg/mL. The median patient with 750 mg or 1000 mg q6h 
achieved the PD target of MIC = 2 µg/mL, but not for MIC = 4 µg/mL. 
We also explored the impact of each of the three significant covariates, namely CrCl4h, total body 
weight and serum albumin, on PTA. In Table S1 (of supplementary materials), we computed the PTA 
for the dose of 1000 mg q8h (the dosage regimen of the protocol) and 750 mg q6h (same daily dose) 
for three percentiles of each covariate (10th, 50th and 90th), assuming the two remaining covariates 
were at their median value. For both dosing regimens, 40% fT > MIC was obtained for the target MICs 
2 µg/mL and 4 µg/mL for all values of the covariates. Figure S1 shows the concentration profile at 
steady state for 750 mg q6h for the various covariate values. It illustrates the rather limited impact of 
covariates on fT > MIC for that dosage regimen. 
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Discussion 
We studied the pharmacokinetics of imipenem after I.V. infusion in 51 critically ill patients 
hospitalised in an ICU with suspected Gram negative VAP, using a population approach. We found 
that imipenem concentrations were best described by a two-compartment model in accordance with 
previously published studies (14,17,18). The strength of our study is the number of patients with 
prospective collection of kinetic profiles with 6 points and a central laboratory for concentration 
assessment. To the best of our knowledge, the present study is the first study of imipenem PK using a 
population approach in the ICU. 
In the population PK study performed by Lee et al. (5) in healthy subjects, estimated imipenem 
clearance was 12.1 L/h and estimated central volume was 9.7 L. In ICU patients, we found a very 
similar clearance. The volume of distribution was estimated to 20.4 L in the final model, which is 
twice higher than that described in a healthy population. This increase is consistent with the clinical 
status of ICU patients. Indeed, inflammatory response in sepsis lead to an increased capillary 
permeability, with fluid flow to the extracellular compartment (edema development). McKindley et 
al. (15) reported an increased volume of distribution in ICU patients with VAP. Similarly, Novelli et al. 
(17) enhanced the impact of sepsis on the volume of distribution with a new compartment, the third 
compartment for critically ill patients with sepsis. 
For covariate selection we used a standard stepwise approach rather than a more modern 
approaches (such as the lasso method associated with cross-validation (37)). Results of the selection 
steps were very consistent with our rich pharmacokinetic design. Of the 12 covariates studied, we 
found that CrCl4h, total body weight and serum albumin have a significant impact on the PK variability 
of imipenem. The addition of these three covariates reduces the variability of imipenem clearance 
and central Vd with a decrease of 10% for CL and 17% for V1. A recent study by Yoshizawa et al. (38) 
also showed the impact of creatinine clearance on imipenem clearance in patients with altered renal 
function. The other covariates tested, namely age and body weight, were not kept in their model. 
Estimates of pharmacokinetic parameters CL and V1 were 8 L/h and 11.4 L, respectively, with a 
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median CrCL = 54.1 mL/min, and were lower than those estimated in our population. In our study, 
we observed high values of creatinine clearance. These high values are consistent with the 
hyperdynamic state of sepsis patients and confirmed the physiological impact on the PK parameters 
(39). It is therefore necessary to regularly control this creatinine clearance parameter in ICU to limit 
an effect on the clearance of imipenem although this effect was limited in our final PK model (Figure 
S1). A similar process of recorded creatinine clearance was previously described by Belzberg et al. 
(14) during 2 hours with maximum value of 408 mL/min. in accordance with our study, this study did 
not found an influence of creatinine clearance on imipenem clearance but an increase of distribution 
volume. 
The hydrophilic nature of imipenem makes it sensitive to changes in the distribution of body fluids. 
Its volume of distribution is affected by all disorders resulting in an increase of the extracellular 
compartment such as sepsis or clinically revealed by edema. In our study, we did not find any effect 
of edema on imipenem volume of distribution in the PK model but total body weight and serum 
albumin were found to influence significantly the distribution of imipenem and probably were 
reflected the physiological characteristics encountered in the ICU. The same increase of central 
volume was also observed for another antibiotic class, the aminoglycosides. Tanigawara et al. (40) 
showed a significant increase of volume of distribution in a comparative study between healthy 
subjects and patients with pneumonia or sepsis treated by arbekacin hydrophilic and low protein 
binding antibacterial agents as imipenem. For results of Figure 2 and total body weight estimate 
coefficient, we evaluated the volume with a coefficient of total body weight fixed to one. The 
volumes expressed as L/kg were very similar between the final model and the total body weight 
coefficient model, 0.26 L/kg and 0.27 L/kg respectively. Due to the hydrophilic property of this 
antibacterial agent, we wished to evaluate other weight metrics (as ideal body weight or lean body 
weight) but these parameters could unfortunately not be collected during patient monitoring. No 
other covariates, especially ICU scores, were found in the PK model and considered for 
determination of the dosage regimen of imipenem.  
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With the PK results, we also performed a Monte Carlo simulation to evaluate several dosage 
regimens with doses given q6h or q8h. In the context of suspected VAP due to Gram-negative bacilli, 
we focused our simulations on the target MICs of 2 and 4 µg/mL (sensitivity breakpoint of 
Enterobacteriaceae species and Pseudomonas aeruginosa, respectively). With the same daily dose of 
3 g, a q6h infusion led to a PD objective greater than 40% fT > MIC for those two target MICs. Despite 
their impact on the variability of PK parameters, the covariates lead to rather small changes in PK 
parameters and concentration profiles and thus have a limited effect on PTA, and we show rather 
small changes in the PTA 40% fT > MIC. Our evaluation of the 3 g daily dose has confirmed that q6h is 
a good dosage regimen for use in the ICU. This dose did not exceed the threshold of toxicity and the 
q6h regimen was optimised to take into account the higher PK variability seen in critically ill patients. 
Conclusion 
Our results demonstrate that imipenem pharmacokinetics vary in ICU patients. Imipenem clearance 
CL and central volume V1 were best estimated with three covariates whose influence on 
pharmacokinetic estimates was limited. Using population pharmacokinetic parameters, we showed 
that an infusion 750 mg q6h dosage regimen (3 g daily dose) is needed to achieve adequate 
pharmacodynamics, i.e., a fraction of time above MIC greater than 40% for usual the MICs of 2 and 4 
µg/mL.  
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Figure legends: 
Figure 1: Spaghetti plot of imipenem concentrations versus time following four doses for the 51 ICU 
patients included in the analysis. Data above LOQ are presented as blues circles, BQL data as red 
circles at LOQ. 
Figure 2: Relationship between estimated individual pharmacokinetic parameters and covariates: (a) 
clearance vs. 4-hour creatinine clearance (b) central volume vs. total body weight (c) central volume 
vs. serum albumin. Model predictions are displayed as the red curve. 
Figure 3: Goodness-of-fit plots for the final model with covariates: (a) Observations and (b) 
population weighted residuals (PWRES) versus population predicted values; (c) observations and (d) 
individual weighted residuals (IWRES) versus individual predicted values. Observations are plotted as 
blue circles and BQL data as red circles. LOWESS smoothed curve are plotted as blue curves. 
Figure 4: (a) Visual Predictive Check (VPC) and (b) Normalized Prediction Distribution Error (NPDE) 
versus time since first dose for the final model. VPC details:  the solid green lines indicate the 10th, 
50th and 90th percentiles for observed data. The shaded blue and pink areas represent 90% prediction 
intervals from the corresponding percentiles calculated from simulated data. Observations are 
plotted as blue circles and BQL data as red circles. 
Figure 5: Simulated probabilities of pharmacodynamic target attainment versus MIC for various 
imipenem current dosage regimens at steady state (a) 40 % fT > MIC and (b) 100 % fT > MIC. Vertical 
lines are displayed for MIC = 2 µg/mL and MIC = 4 µg/mL which are the thresholds currently observed 
for Gram-negative bacteria in the ICU. 
Figure 6: Predicted concentrations of imipenem for median value of parameters for 1000 mg q8h or 
1000 mg q6h or 750 mg q6h.  
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Table 1: Characteristics at inclusion or at time of PK collection (4th dose) of the 51 ICU patients included in the PK analysis 
Parameters Value* 
At inclusion  
Male  41 (80 %) 
Age (years) 60 [28-84] 
Total body weight (kg) 77 [45-126] 
SAPS II  40 [19-74] 
At time of 4th dose  
Weight change# (kg) 1.1 [-18.1-19.1] 
SOFA 6 [2-14] 
Oedema score  7 [0-18] 
Serum albumin (g/L)** 18 [10-28] 
CrCl4h (mL/min) 86.4 [9.1-571.4] 
Shock  18 (35 %) 
PEEP (cmH2O) 6 [0-13] 
PaO2/FiO2 182 [81-346] 
* Values are expressed as median [min-max] or number (percent) 
  
  
# between the 4th dose and admission 
 
 
** median value for 9 patients 
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Table 2: Population PK parameters of imipenem in 51 ICU patients 
 Basic model Final model 
 Value RSE
* 
(%) 
Value RSE
* 
(%) 
p-value** Median 
bootstrap# 
95% CIs 
bootstrap# 
Fixed effects        
CL (L/h) 13.0 6 13.2 5  13.2 11.4 – 15.3 
βCrCL4h (log L/h) - - 0.2 19 6.4 10-5 0.25 0.1 – 0.4 
V1 (L) 22.4 9 20.4 7  19.8 14.9 – 25.4 
βWeight (log L) - - 1.3 17 1.3 10-4 1.2 0.6 – 2.2 
βSerum albumin (log L) - - -1.1 18 1.8 10-4 -1.0 -1.8 – -0.5 
Q (L/h) 10.1 28 12.2 25  12.3 4.7 – 20.3 
V2 (L) 9.9 14 9.8 13  10.5 6.9 – 13.7 
Between-subject variability      
ωCL (%) 48 10 38 13  36 26 – 49 
ωV1 (%) 48 15 31 18  22 1 – 45 
Correlation        
𝜂𝐶𝐿𝑖𝜂𝑉1𝑖 
 
0.48 29 0.51 28  0.79 -1 – 1 
Residual variability        
σ (%) 33 4 33 3  34 26 – 41 
BIC 1595 - 1560 -  -  
* RSE: relative standard error; ** Likelihood ratio test (LRT); # from 1000 bootstrap resampling.  
Final population PK covariate model is: 𝐶𝐿𝑖 = 13.2 × (
𝐶𝑟𝐶𝐿𝑖
86.4
)0.2 𝑎𝑛𝑑 𝑉1𝑖 =  20.4 × (
𝑤𝑒𝑖𝑔ℎ𝑡
77
)1.3 ×
(
𝑎𝑙𝑏𝑢𝑚𝑖𝑛
18
)−1.1. 
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Table 2: Summary of covariates model building 
Model 
Number of 
covariates 
- 2LL BIC ΔBIC 
Basic model 0 1563 1595 - 
CrCL on CL 1 1541 1577 -18 
CrCL and age on CL 2 1536 1573 - 22 
CrCL and age on CL 
Weight on V1 
3 1527 1571 - 24 
CrCL and age on CL 
Weight and Alb on V1 
4 1510 1557 - 38 
CrCL and age on CL 
Weight, Alb and ES on V1 
5 1508 1559 - 36 
 
Alb = Serum albumin; -2LL = - 2 *log - likelihood; ΔBIC = BIC ( model step) – BIC (basic 
model)  
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Table S1: Expected fractional time above MIC (fT > MIC) for two target MICs 2 and 4 µg/mL for 1000 mg q8h and 750 mg 
q6h dosage regimen and population parameters for the 10th, 50th and 90th percentiles of the three significant covariates. 
 
1000 mg q8h 
MIC = 2 µg/mL MIC = 4 µg/mL 
10th  50th 90th  10th  50th 90th  
 CrCl4h* 100 86.5 66.5 97.2 63.7 48.1 
Body weight** 72.7 86.5 100.0 53 63.7 77.4 
Serum albumin*** 100.0 86.5 78.0 80.0 63.7 57.7 
750 mg q6h 
MIC = 2 µg/mL MIC = 4 µg/mL 
10th  50th 90th  10th  50th 90th  
CrCl4h* 100 100 79.9 100 74.8 55.2 
Body weight** 88.0 100 100 63.1 74.9 92.0 
Serum albumin*** 100 100 94.7 95.3 74.9 67.7 
* 10th = 17 mL/min; 50th = 86.4 mL/min and 90th = 258 mL/min  
** 10th = 53 kg; 50th = 77 kg and 90th = 111 kg 
*** 10th = 11 g/L; 50th = 18 g/L and 90th = 23 g/L 
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Figure S1 : Predicted steady-state concentrations of imipenem for 750 mg q6h dosage regimen with 
percentile values (10th, 50th and 90th) of the three significant covariates: 
With (a) Creatinine clearance percentiles: 10th = 17 mL/min; 50th = 86.4 mL/min; 90th = 258 mL/min 
(b) Body weight: 10th = 53 kg; 50th = 77 kg; 90th = 111 kg 
(c) Serum albumin: 10th = 11 g/L; 50th = 18 g/L; 90th = 23 g/L 
Vertical lines are displayed for MIC = 2 μg/mL and MIC = 4 μg/mL. 
